Link to this page
National Cancer Institute Thesaurus
Last uploaded:
February 23, 2024
Jump to:
| Preferred Name | Rifaximin | |
| Synonyms |
RIFAXIMIN Rifaximin Xifaxan |
|
| Definitions |
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61926 |
|
| CAS_Registry |
80621-81-4
|
|
| Chemical_Formula |
C43H51N3O11
|
|
| code |
C61926
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
| Contributing_Source |
CTRP FDA
|
|
| DEFINITION |
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract.
|
|
| Display_Name |
Rifaximin
|
|
| FDA_UNII_Code |
L36O5T016N
|
|
| FULL_SYN |
RIFAXIMIN Rifaximin Xifaxan
|
|
| label |
Rifaximin
|
|
| Legacy Concept Name |
Rifaximin
|
|
| NCI_Drug_Dictionary_ID |
654589
|
|
| PDQ_Closed_Trial_Search_ID |
654589
|
|
| PDQ_Open_Trial_Search_ID |
654589
|
|
| Preferred_Name |
Rifaximin
|
|
| prefixIRI |
Thesaurus:C61926
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0073374
|
|
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping